References
- Kantrowitz JT. How do we address treating the negative symptoms of schizophrenia pharmacologically? Expert Opin Pharmacother. 2021;1–3. DOI:10.1080/14656566.2021.1939677
- Calabrese F, Tarazi FI, Racagni G, et al. The role of dopamine D 3 receptors in the mechanism of action of cariprazine. CNS Spectr. 2020;25(3):343–351.
- Girgis RR, Slifstein M, D’Souza D, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology (Berl). 2016;233(19–20):3503–3512.
- Collo G, Mucci A, Giordano GM, et al. Negative symptoms of schizophrenia and dopaminergic transmission: translational models and perspectives opened by iPSC techniques. Front Neurosci. 2020;14:632.
- Simpson EH, Winiger V, Biezonski DK, et al. Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition. Biol Psychiatry. 2014;76(10):823–831.
- Galderisi S, Mucci A, Buchanan RW, et al. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664–677.
- Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939–951.
- Krause M, Zhu Y, Huhn M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268(7):625–639.
- Leucht S, Davis JM. Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. Lancet. 2017;389(10074):1077–1078.
- Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–1113.
- Earley W, Guo H, Daniel D, et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data. Schizophr Res. 2019;204:282–288.
- Rancans E, Dombi ZB, Mátrai P, et al. The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study. Int Clin Psychopharmacol. 2021;36:154–161.
- Molnar MJ, Jimoh IJ, Zeke H, et al. Early-onset schizophrenia with predominantly negative symptoms: a case study of a drug-naive female patient treated with cariprazine. Front Pharmacol. 2020;11:477.
- Hho M, Moeller S. Decline in psychotic symptoms in addition to cardiac and metabolic safety with cariprazine after poor response to previous antipsychotic treatments – a series of two cases. Neuropsychiatr Dis Treat. 2021;17:1089–1093.
- Vink EE, Azoulay E, Caplan A, et al. Time-limited trial of intensive care treatment: an overview of current literature. Intensive Care Med. 2018;44:1369–1377.